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Abstract
Data on 205 children who underwent retrograde arterial catheterisation were studied to assess the frequency of femoral artery thrombosis and the safety and efficacy of systemic streptokinase treatment for this complication. In 29 (14%) a transarterial balloon dilatation was performed. In 15 (7-3%) patients impaired arterial perfusion due to vascular spasm with or without thrombus formation was seen in the cannulated leg after catheterisation. Despite heparinisation, signs of impaired arterial circulation persisted in nine patients (4-4% of the total). In these patients femoral artery thrombosis was strongly suspected. Six Before and after catheterisation the arterial perfusion of both legs was assessed by examination of arterial pulses, blood pressure, colour, and temperature. Patients with absent or reduced arterial pulsations, substantially decreased blood pressure, pallor, and diminished skin temperature of the cannulated leg shortly after the end of the procedure were considered to have impaired arterial perfusion due to arterial spasm with or without thrombus formation. We studied the data on these patients.
In all these patients heparin was administered for different times and monitored by the activated partial thromboplastin time. In patients with persistent signs of impaired arterial circulation despite heparinisation a tentative diagnosis of arterial thrombosis was made and streptokinase was used for systemic thrombolytic treatment.
The distribution of age and weight (mean (SD)) and also the interval (mean (SD)) between the end of the catheterisation and the start of streptokinase treatment were determined. The duration of treatment (mean (SD)) was also assessed.
Before and during streptokinase treatment prothrombin time, activated partial thromboplastin time, and plasma fibrinogen concentrations were recorded in all patients; in some patients the thrombin time was also measured. Two hours after the end of streptokinase treatment heparinisation was restarted in all patients to prevent re-thrombosis after successful treatment or persisting thrombus formation after treatment failure. This was continued for 12 hours.
Results
Shortly after the end of the catheterisation 15 (7-3%) of 205 patients showed impaired arterial perfusion of the cannulated leg. In six (40%0) of these the arterial circulation became normal during systemic heparin treatment. Despite continued heparinisation arterial perfusion remained impaired in the remaining nine patients (60%, 4-40% of 205 patients) (table 1) . Six of these nine patients had undergone a transarterial balloon dilatation. The median weight of these children was 12 6 (8 1) kg (range 3 2-25 4 kg); five of them weighed less than 10 kg. The median age was 3 9 (4-3) years (range 9 days-I 1 years). During systemic streptokinase treatment (table 2) arterial perfusion became normal in eight (89o0) of nine patients after 7-120 hours (mean 39 6 (38 9) hours). Because of persisting impaired perfusion after 24 hours of treatment the streptokinase dose was increased in one patient (patient 7, table 2) after another loading dose. This resulted in normal arterial circulation after 45 hours. In the youngest patient (patient 9, table 2) absence of pulses and low systolic blood pressure persisted despite laboratory signs of adequate fibrinolysis. After 72 hours thrombolytic treatment in this patient was stopped. However, femoral artery perfusion was normal 5 days after the end of streptokinase treatment. There were no signs of re-thrombosis at follow up after 3-20 months in any patient. During streptokinase treatment the prothrombin time and partial thromboplastin time did not change. The thrombin time increased (from 17 9 (3 8)s to 31 9 (110)s, mean relative increase of 0-85 (0-61) and the plasma fibrinogen concentration decreased (from 2 8 (0 6) g/l to 1 6 (0 7) g/l, mean relative decrease of 0 42 (0-24)). The fibrinogen concentration did not change in patient 6, in whom streptokinase treatment resulted in a normal circulation after 45 hours (table 3) .
There was no substantial bleeding during or after streptokinase treatment except for minimal bleeding at the arterial entry site that could be stopped by groin compression. No allergic reactions were seen. (11 o) (the youngest in our series (9 days old)). Femoral artery perfusion was normal after 5 days, however. Recanalisation after spontaneous resolution of the thrombus is highly unlikely to have occurred in such a short period. Failure of thrombolytic treatment in neonates may be attributed to the lower concentrations of plasminogen or because the functional activity of plasminogen is less than the concentrations of plasminogen inhibitors (especially a2 antiplasmin).12-14 Sometimes the use of massive amounts of thrombolytic agents may be successful in these cases.'4 Activation of plasminogen by thrombolytic agents can result in haematological changes (particularly an increase of thrombin time and a decrease in plasma fibrinogen as well as an increase in plasma fibrin degradation products).'°15 Monitoring of prothrombin time, partial thromboplastin time, thrombin time, plasma fibrinogen, and fibrin degradation products is a useful guide to adjusting thrombolytic treatment to avoid systemic bleeding complications.' 1 15 In our patients there was no lengthening of prothrombin time and partial thromboplastin time, but the thrombin time increased and there was a moderate decrease in plasma fibrinogen concentrations-both signs of fibrinolysis (table 3) .
Bleeding is the most hazardous complication of systemic thrombolytic treatment. We saw no serious bleeding complications in our study. Bleeding from the arterial entry site is the most common complication-particularly in patients undergoing balloon dilatation procedures. This complication was seen in one of our patients. Local To avoid re-thrombosis after successful thrombolytic treatment or when thrombus formation persisted after treatment failure we treated our patients with heparin. The optimal anti-thrombotic regimen to prevent these problems still needs to be established. Heparin and/or aspirin have been recommended.'6 Like other investigators we did not encounter rethrombosis in our patients.45
Treatment with streptokinase (a bacterial problem) is occasionally associated with an allergic reaction (rash, fever, nausea, a syndrome resembling serum sickness, and anaphylactic shock) especially in patients exposed to a recent streptococcal infection or streptokinase treatment.'0 Urokinase, a human product, is non-antigenic and can be used instead of streptokinase.'0 There were no allergic reactions in our patients.
The doses that we used and those used by others in children were not established by pharmacological investigations but were estimated from experience in adult patients. These doses were safe and effective but we do not know whether they are pharmacologically optimal.
In our study group the early use of streptokinase in the treatment of femoral artery thrombosis after percutaneous retrograde catheterisation in infants seemed to be beneficial. Because proof of the efficacy of treatment with streptokinase cannot be drawn from this study we recommend that a randomised, controlled study should be undertaken.
